Author:
Xing Yang,Yasinjan Feroza,Du Yajie,Geng Huayue,Zhang Ying,He Minghua,Guo Rui,Yang Lei,Cui Jiayue,Mu Dongmei,Liu Ziling,Wang Hong
Abstract
BackgroundCervical cancer is the fourth most cancer and the fourth leading cause of cancer-related deaths in women worldwide. Current treatment for patients with advanced cervical cancer is limited. And in the urgent demand for novel effective therapies both as the first and the second line treatment for these patients, immunotherapy is developing fast and has made some achievements.MethodsThis study incorporated 1,255 topic-related articles and reviews from 1999 to 2022 in the Web of Science Core Collection (WoSCC). The WoS platform, Citespace, and VOS viewer provided the annual distribution of publications and citations, the analysis of researching countries and institutions, references, keywords (co-occurrence analysis, burst analysis, and timeline view analysis), and researching authors, respectively. For clinical trials, 720 trials and 114 trials from ClinicalTrials.gov and ICTRP were retrieved, respectively. And 296 trials were finally incorporated into the analysis.ResultsThe scientometric analysis showed that the study of immunotherapies in cervical cancer developed fast in recent years. Most publications were from the United States, followed by China. Seven of the top 10 co-cited references belong to clinical trials, and five of them were published in recent five years. There are lots of clinical trials us specific treatment patterns, some of which have represented excellent effects.ConclusionsBoth the scientometric analysis of the 1,255 publications and the analysis of clinical trials showed that the field of immunotherapies in cervical cancer developed so fast in recent years. It was found that a lot of clinical trials using various immunotherapies (mainly vaccine therapy, adoptive cell therapy, immune checkpoint blockade, and antibody-drug conjugate) for advanced cervical cancer are currently ongoing or have represented considerable effect. Centered in immunotherapies, immune checkpoint blockades have represented great efficacy and huge potential, especially combined with other therapies such as chemotherapy, targeted therapy, and other immunotherapies.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Jilin Province
National College Students Innovation and Entrepreneurship Training Program
Subject
Immunology,Immunology and Allergy
Reference90 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
3. Cancer incidence and mortality in China, 2016;Zheng;J Natl Cancer Center,2022
4. Screening for cervical cancer: US preventive services task force recommendation statement;Curry;Jama,2018
5. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017;Liao;JAMA Netw Open,2022
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献